These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8343902)

  • 1. Lipoprotein levels following treatment with cyproterone acetate or LHRH analogues.
    Gillatt DA; Bolton CH; Chadwick D; Downs LG; Hopton MI; Gingell JC
    Br J Urol; 1993 Jun; 71(6):728-30. PubMed ID: 8343902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of cyproterone acetate and a long-acting LHRH analogue on serum lipoproteins in patients with carcinoma of the prostate.
    Paisey RB; Kadow C; Bolton C; Hartog M; Gingell JC
    J R Soc Med; 1986 Apr; 79(4):210-1. PubMed ID: 2939240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma.
    Thorpe SC; Azmatullah S; Fellows GJ; Gingell JC; O'Boyle PJ
    Eur Urol; 1996; 29(1):47-54. PubMed ID: 8821690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
    Lamberts SW; Uitterlinden P; de Jong FH
    Cancer Res; 1988 Nov; 48(21):6063-8. PubMed ID: 2844399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.
    Sugiono M; Winkler MH; Okeke AA; Benney M; Gillatt DA
    Prostate Cancer Prostatic Dis; 2005; 8(1):91-4. PubMed ID: 15711607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the LHRH analogue zoladex depot alone and in combination with cyproterone acetate in the treatment of advanced prostatic cancer.
    Di Silverio F; Serio M; Costantini A
    J Chemother; 1989 Jul; 1(4 Suppl):1231-4. PubMed ID: 16312846
    [No Abstract]   [Full Text] [Related]  

  • 7. Paradoxical effects of the anti-androgen cyproterone acetate on lipid and lipoprotein metabolism.
    Wynn V; Godsland IF; Seed M; Jacobs HS
    Clin Endocrinol (Oxf); 1986 Feb; 24(2):183-91. PubMed ID: 2940034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma lipoproteins during treatment with cyproterone acetate in men with prostatic carcinoma.
    Wallentin L; Varenhorst E
    J Clin Endocrinol Metab; 1980 Nov; 51(5):1118-22. PubMed ID: 7419687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.
    Bruchovsky N; Goldenberg SL; Akakura K; Rennie PS
    Cancer; 1993 Sep; 72(5):1685-91. PubMed ID: 7688656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome.
    Mhao NS; Al-Hilli AS; Hadi NR; Jamil DA; Al-Aubaidy HA
    Diabetes Metab Syndr; 2016; 10(1 Suppl 1):S95-8. PubMed ID: 26703220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cyproterone acetate (CPA) on serum lipoproteins when administered alone and in combination with ethinyl estradiol (EE).
    Lindberg UB; Crona N; Enk L; Samsioe G; Silfverstolpe G
    Horm Metab Res; 1987 May; 19(5):222-5. PubMed ID: 2953663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.
    Goldenberg SL; Bruchovsky N; Gleave ME; Sullivan LD; Akakura K
    Urology; 1995 May; 45(5):839-44; discussion 844-5. PubMed ID: 7538246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cyproterone acetate: cardiovascular tolerance].
    Hermabessière J
    Prog Urol; 1992 Apr; 2(2):226-33. PubMed ID: 1302058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial.
    Irani J; Salomon L; Oba R; Bouchard P; Mottet N
    Lancet Oncol; 2010 Feb; 11(2):147-54. PubMed ID: 19963436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The treatment of prostatic carcinoma with cyproterone acetate].
    Tsvetkov M; Mladenov D; Kumanov Kh
    Khirurgiia (Sofiia); 1996; 49(1):12-5. PubMed ID: 8975080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol ester metabolism in plasma during estrogen and antiandrogen treatment in men with carcinoma of the prostate.
    Wallentin L; Varenhorst E
    J Lab Clin Med; 1981 Dec; 98(6):906-16. PubMed ID: 6458644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
    Bolla M; Gonzalez D; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Gil T; Collette L; Pierart M
    N Engl J Med; 1997 Jul; 337(5):295-300. PubMed ID: 9233866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal management of prostatic cancer.
    Jolobe OM; Khan A
    Br J Hosp Med; 1993 Oct 20-Nov 2; 50(8):493. PubMed ID: 8275295
    [No Abstract]   [Full Text] [Related]  

  • 19. Improved prostate cancer treatment.
    Health News; 2002 Sep; 8(9):8. PubMed ID: 12229905
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of advanced carcinoma of the prostate by LHRH-agonists.
    Claes HI; Vandenbussche L; Vereecken RL
    Prog Clin Biol Res; 1987; 243A():229-37. PubMed ID: 2958853
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.